Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already ...

The race to supply obesity drugs is so competitive that one early-stage startup is already striking a deal for commercial ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies ...

U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center in Indiana that will focus on ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China ...

Amgen (AMGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Yee from ...

The pharma company said it believes there’s plenty of room for multiple industry players in the obesity drug market.

Find out more about five biomimicry companies harnessing nature’s wisdom to create drug candidates for the benefit of human ...

The center, Lilly Medicine Foundry, will focus on researching new ways of producing medicines and scaling up the production ...